Literature DB >> 15944862

Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon beta 1B.

Eleonora Cocco, Elena Mamusa, Nicola Carboni, Giovanni Marrosu, Alessandro Vannelli, Maria Giuseppina Mascia, Antonella Sirca, Maria Giovanna Marrosu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15944862     DOI： 10.1007/s00415-005-0876-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

1.  Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy.

Authors:  T Kuntzer; A J Radziwill; R Lettry-Trouillat; C Naegeli; F Ochsner; B Erne; A J Steck; J Bogousslavsky
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

2.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.

Authors:  Marion Main; Harvey Kairon; Eugenio Mercuri; Francesco Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2003       Impact factor: 3.140

Review 3.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Pieter A van Doorn; Liselotte Ruts
Journal:  Curr Opin Neurol       Date:  2004-10       Impact factor: 5.710

4.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome.

Authors:  R P Kleyweg; F G van der Meché; P I Schmitz
Journal:  Muscle Nerve       Date:  1991-11       Impact factor: 3.217

5.  Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R D Hadden; B Sharrack; S Bensa; S E Soudain; R A Hughes
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

6.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R Hughes; S Bensa; H Willison; P Van den Bergh; G Comi; I Illa; E Nobile-Orazio; P van Doorn; M Dalakas; M Bojar; A Swan
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

7.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

8.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination.

Authors:  I Pirko; N L Kuntz; M Patterson; B M Keegan; B G Weinshenker; M Rodriguez
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
View more
  2 in total

Review 1.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 2.  [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

Authors:  H-P Hartung; J Haas; M Meergans; F Tracik; S Ortler
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.